

## Opportunities and efficiencies



The focus will be on accelerating R&D with technology and operational efficiencies.

**AI market in drug discovery expected to ↑ from US\$159.8 million to US\$2.9 billion in 2018-25 at a CAGR of 52.9%.**

Almost 180 startups were involved in applying AI to drug discovery.


**It's trending** – AI startups are specifically working on repurposing existing drugs or generating novel drug candidates using AI, machine learning, and automation.

### How are stakeholders dealing with this?

- Build cloud computing capabilities to extend collaboration with other biopharma companies, smaller biotech companies, research institutions, and academia
- Leverage partnerships to explore AI-driven R&D and lay groundwork for more advanced data strategies.
- Digitize the core along with intelligent automation in manufacturing can help companies reduce the go-to-market cycle for drugs



**A service for unlocking many data sources that have traditionally been locked in siloes across multiple organizations remains a critical need. The goal is to enable health care stakeholders to create scalable and secure collaborative business models and reimagine how they approach research, clinical trials, pharmacovigilance, population health, and reimbursement.**



Beginning in 2020, it's anticipated that there will be over **200** new applications for gene and cell therapies per year.

Number of approvals for proprietary medical algorithms continues to rise. An AI algorithm embedded on-device was recently approved.

▶ [Learn more at www.deloitte.com/lifesciencesoutlook](http://www.deloitte.com/lifesciencesoutlook)

# Deloitte.

#### About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. Please see [www.deloitte.com/about](http://www.deloitte.com/about) for a more detailed description of DTTL and its member firms. Deloitte provides audit, consulting, financial advisory, risk management, tax and related services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries and territories, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte's more than 200,000 professionals are committed to becoming the standard of excellence.

#### Disclaimer

This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the "Deloitte Network") is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

#### About Life Sciences and Health Care at Deloitte Touche Tohmatsu Limited

The Deloitte Touche Tohmatsu Limited's life sciences and health care (LSHC) industry group is composed of more than 12,000 professionals in more than 90 countries. These member firm professionals understand the complexity of today's life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today's environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information about the DTTL LSHC industry group, email [dttlshc@deloitte.com](mailto:dttlshc@deloitte.com) or access [www.deloitte.com/healthcare](http://www.deloitte.com/healthcare).  
©2020. For more information, contact Deloitte Touche Tohmatsu Limited.